These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
347 related articles for article (PubMed ID: 19104452)
1. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse. Egberts F; Hitschler WN; Weichenthal M; Hauschild A Melanoma Res; 2009 Feb; 19(1):31-5. PubMed ID: 19104452 [TBL] [Abstract][Full Text] [Related]
2. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma. Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447 [TBL] [Abstract][Full Text] [Related]
3. Use of S-100B to evaluate therapy effects during bevacizumab induction treatment in AJCC stage III melanoma. Kruijff S; Bastiaannet E; Brouwers AH; Nagengast WB; Speijers MJ; Suurmeijer AJ; Hospers GA; Hoekstra HJ Ann Surg Oncol; 2012 Feb; 19(2):620-6. PubMed ID: 21861214 [TBL] [Abstract][Full Text] [Related]
4. Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma. Bánfalvi T; Boldizsár M; Gergye M; Gilde K; Kremmer T; Ottó S Pathol Oncol Res; 2002; 8(3):183-7. PubMed ID: 12515998 [TBL] [Abstract][Full Text] [Related]
5. The value of pre operative S-100B and SUV in clinically stage III melanoma patients undergoing therapeutic lymph node dissection. Kruijff S; Bastiaannet E; Speijers MJ; Kobold AC; Brouwers AH; Hoekstra HJ Eur J Surg Oncol; 2011 Mar; 37(3):225-32. PubMed ID: 21277729 [TBL] [Abstract][Full Text] [Related]
6. S-100B: a stronger prognostic biomarker than LDH in stage IIIB-C melanoma. Wevers KP; Kruijff S; Speijers MJ; Bastiaannet E; Muller Kobold AC; Hoekstra HJ Ann Surg Oncol; 2013 Aug; 20(8):2772-9. PubMed ID: 23512078 [TBL] [Abstract][Full Text] [Related]
7. Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients. Domingo-Domènech J; Castel T; Auge JM; Garcia-Albeniz XA; Conill C; Puig S; Vilella R; Matas J; Malvehy J; Gascón P; Mellado B; Molina R Tumour Biol; 2007; 28(5):264-72. PubMed ID: 17962723 [TBL] [Abstract][Full Text] [Related]
8. The predictive power of serum S-100B for non-sentinel node positivity in melanoma patients. Damude S; Hoekstra HJ; Bastiaannet E; Muller Kobold AC; Kruijff S; Wevers KP Eur J Surg Oncol; 2016 Apr; 42(4):545-51. PubMed ID: 26831006 [TBL] [Abstract][Full Text] [Related]
9. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein. Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767 [TBL] [Abstract][Full Text] [Related]
10. Heterogenous S-100B protein expression patterns in malignant melanoma and association with serum protein levels. Bánfalvi T; Udvarhelyi N; Orosz Z; Gergye M; Gilde K; Tímár J Oncology; 2003; 64(4):374-9. PubMed ID: 12759535 [TBL] [Abstract][Full Text] [Related]
11. Serum S100B and LDH are not useful in predicting the sentinel node status in melanoma patients. Egberts F; Momkvist A; Egberts JH; Kaehler KC; Hauschild A Anticancer Res; 2010 May; 30(5):1799-805. PubMed ID: 20592382 [TBL] [Abstract][Full Text] [Related]
12. S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests. Missotten GS; Korse CM; van Dehn C; Linders TC; Keunen JE; Jager MJ; Bonfrer JM Tumour Biol; 2007; 28(2):63-9. PubMed ID: 17264538 [TBL] [Abstract][Full Text] [Related]
13. S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma. Abusaif S; Jradi Z; Held L; Pflugfelder A; Weide B; Meier F; Garbe C; Eigentler TK Melanoma Res; 2013 Oct; 23(5):396-401. PubMed ID: 23907232 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of multiple serum markers in advanced melanoma. Díaz-Lagares A; Alegre E; Arroyo A; González-Cao M; Zudaire ME; Viteri S; Martín-Algarra S; González A Tumour Biol; 2011 Dec; 32(6):1155-61. PubMed ID: 21858537 [TBL] [Abstract][Full Text] [Related]
15. S-100B concentrations predict disease-free survival in stage III melanoma patients. Kruijff S; Bastiaannet E; Kobold AC; van Ginkel RJ; Suurmeijer AJ; Hoekstra HJ Ann Surg Oncol; 2009 Dec; 16(12):3455-62. PubMed ID: 19636631 [TBL] [Abstract][Full Text] [Related]
16. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. Mårtenson ED; Hansson LO; Nilsson B; von Schoultz E; Månsson Brahme E; Ringborg U; Hansson J J Clin Oncol; 2001 Feb; 19(3):824-31. PubMed ID: 11157036 [TBL] [Abstract][Full Text] [Related]
17. [Serum levels of S-100b protein after four years follow-up of patients with melanoma]. Zissimopoulos A; Karpouzis A; Karaitianos I; Baziotis N; Tselios I; Koutis C Hell J Nucl Med; 2006; 9(3):204-7. PubMed ID: 17160167 [TBL] [Abstract][Full Text] [Related]
18. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma. Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178 [TBL] [Abstract][Full Text] [Related]
19. Value of tumour marker S-100B in melanoma patients: a comparison to 18F-FDG PET and clinical data. Reinhardt MJ; Kensy J; Frohmann JP; Willkomm P; Reinhold U; Grünwald F; Biersack HJ; Bender H Nuklearmedizin; 2002 Jun; 41(3):143-7. PubMed ID: 12109034 [TBL] [Abstract][Full Text] [Related]
20. Value of serum S-100B for prediction of distant relapse and survival in stage III B/C melanoma. Smit LH; Nieweg OE; Mooi WJ; Bonfrer JM; Haanen JB; Kroon BB; De Gast GC Anticancer Res; 2008; 28(4C):2297-302. PubMed ID: 18751409 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]